Now let me write the final consolidated review.

## Summary
This paper investigates whether LLMs (both embedding and generative models) can complement single-cell foundation models for cell type classification. It introduces scMPT, a fusion model that combines frozen embeddings from the text encoder Ember-V1 and the single-cell foundation model scGPT via a small trainable MLP. Through interpretability analysis (integrated gradients and LIME) and ablation studies, the paper shows that text encoders leverage marker gene knowledge, while also revealing that non-biological factors (lexical/syntactic similarity) contribute to performance. The paper further demonstrates that simply providing a list of possible cell types unlocks GPT-4o's zero-shot cell type classification from 0% to competitive levels.

## Strengths
- **Interpretability analysis with convergent evidence.** The paper applies two complementary methods (integrated gradients and LIME) to show that Ember-V1 focuses on known marker genes when predicting cell types. The agreement between methods — "the markers highlighted by integrated gradients were almost an exact subset of the markers highlighted by LIME" — is stronger evidence than either method alone. The cosine similarity analysis (Table 8) provides a third, independent line of evidence. This is the paper's strongest analytical contribution.
- **Ablation study that honestly disentangles biological from non-biological factors.** Replacing gene names with SHA-256 hashes and shuffling gene order (Table 5) cleanly separates the contributions of biological content from lexical/syntactic structure. The paper candidly reports that both encoders retained some performance even after both ablations, and thoughtfully discusses what this implies — including the honest observation that "high classification and clustering performance alone does not demonstrate an encoder has a strong understanding of the underlying biology."
- **Demonstration that encoder selection matters.** Section 4.1 shows that switching from previously-used encoders (ada-002, all-MiniLM-L12-v2) to Ember-V1, selected systematically from the MTEB benchmark, yields significant improvements across multiple datasets. This provides a practical, actionable finding for the field and justifies the paper's encoder choice.
- **Simple, reproducible finding unlocks generative LLM performance.** Table 2 shows that providing a list of possible cell types raises GPT-4o's accuracy from 0% (corroborating prior work) to competitive levels (up to 92% on Pancreas). The paper also confirms that GPT-4o *without* the label list also gets 0%, isolating the intervention as the cause.

## Weaknesses

### Fatal
None.

### Major
- **scMPT results are only shown for one of seven datasets.** Table 6 reports scMPT's performance only on the Pancreas dataset. The paper claims scMPT "performs competitively with, and often better than the best of the two encoders on each dataset" and that its "performance is notably strong enough that it is even competitive with full fine tunes of scGPT on each dataset" (lines 137–138), but the reader cannot verify these claims for the other six datasets (Bones, Artery, Myeloid, MS, Aorta, Tabula Sapiens). Given that scMPT is the paper's headline contribution — named in the title and abstract — this is a critical gap. The Discussion's qualitative text about scMPT's consistency does not substitute for tabulated quantitative results.
- **No comparison against a late-fusion baseline.** The paper faults GenePT's ensemble approach because "fusion at such a late stage ignores possible synergies between different modalities" (line 50–51). Yet it never tests whether scMPT's early fusion actually outperforms a simple late-fusion baseline (e.g., averaging k-NN predictions or weighted voting of scGPT and Ember-V1). Without this comparison, the claimed advantage of "leveraging synergies" is asserted rather than demonstrated.
- **Cross-paper comparison to scGPT fine-tunes is methodologically unsound.** The claim that scMPT "is even competitive with full fine tunes of scGPT on each dataset, based on results reported in the original scGPT paper" (lines 137–138) relies on numbers from a different study that likely used different preprocessing, train/test splits, and evaluation protocols. A controlled comparison — where scGPT is fine-tuned under identical conditions as scMPT — is required to support this claim.
- **Ember-V1 is not described.** The paper selects Ember-V1 as its primary encoder but provides no information about its architecture, parameter count, training data, or whether it has any biomedical pre-training. This makes the marker-gene interpretability results difficult to contextualize — marker genes are well-known terms that could be captured through general-domain co-occurrence patterns. Without knowing what Ember-V1 was trained on, the reader cannot assess whether its marker gene knowledge reflects genuine biological understanding or surface-level statistical patterns.

### Minor
- **Ablation study conducted on only one dataset (Aorta).** The finding that non-biological factors contribute to encoder performance (Table 5) is important, but different datasets have different biological properties (cell type distinctiveness, expression sparsity), and the relative contribution of biological vs. non-biological factors likely varies. Running the ablation on at least 2–3 additional datasets would strengthen generalizability.
- **Full encoder sweep performed on only one dataset (Aorta).** The six MTEB-selected encoders are compared only on Aorta before selecting Ember-V1 (Table 1). While the paper then compares Ember-V1, ada-002, and all-MiniLM on all datasets, a different encoder might have performed better on some datasets. This is a common experimental design but worth noting as a limitation.
- **scMPT architecture details are vague.** The paper describes the architecture as "a small multi layer perceptron" using "the default architecture for the scikit-learn library's MLP implementation" (line 57) and shows "dense layers" in Figure 1, but provides no specifics on layer sizes, number of layers, activation functions, or regularization. For the fusion network itself, similar detail is missing. This undermines reproducibility.
- **Generative LLM experiments lack measures of uncertainty.** Tables 2 and 7 report accuracy on 100 randomly selected cells per dataset without confidence intervals, standard deviations, or multiple subsample estimates. With n=100, the standard error is non-trivial, making it impossible to assess whether differences between methods are meaningful.

### Trivial
None.

## Nice-to-Haves
- Running the ablation study on multiple datasets would strengthen the generalizability of the findings.
- Reporting precision, recall, and F1 for the generative methods (as is done for embedding methods) would enable more complete cross-method comparison.
- Reporting how often the fallback mechanism was triggered in the GPT-4o+scGPT fusion pipeline would improve transparency.

## Removed Points
- **GPT-4 vs GPT-4o confound (from Harsh Critic):** The critic claimed the improvement over Liu et al. (2023) could reflect model generational advances rather than the label-list prompt. However, the paper explicitly controls for this — GPT-4o *without* the label list also gets 0% (line 105). The criticism is factually wrong and removed.
- **Incomplete reproducibility statement:** The critic noted the statement "breaks off." This is a PDF parsing artifact affecting all papers; it does not reflect an author error. Removed per hard rule.
- **"The paper does not report how often the fallback was triggered":** Too granular for a major weakness; moved to Nice-to-Haves.
- **Overly generic area-of-concern sweeps from the Harsh Critic:** Several framings like "could the metric be measuring a proxy?" or "are confounders controlled?" lacked a concrete anchor in the paper and were removed.
- **Strength Finder's generic/superficial strengths removed:** The original strength about "the paper addresses an important problem" was generic and removed. Only strengths with specific evidence were retained.

## Novel Insights
The most valuable insight from the reviews is that **the paper's strongest contributions are its analytical findings (interpretability and ablation), not its method claim.** The marker-gene attribution analysis with convergent evidence from two methods, combined with the honestly-discussed ablation showing non-biological factors, is genuinely informative and could stand as a useful empirical study. However, the paper packages these findings as supporting context for scMPT, which itself is under-evidenced. The disconnection between what the paper does best (understanding LLM behavior on cell sentences) and what it foregrounds (a new fusion model) is the central tension the authors need to resolve.

## Suggestions
- Present a **comprehensive table of scMPT results across all seven datasets** alongside unimodal baselines and a late-fusion baseline (e.g., averaged k-NN predictions or weighted voting of scGPT and Ember-V1). This would directly test the claimed synergy advantage and is the single highest-leverage improvement.
- Either **run a controlled fine-tuning experiment** comparing scMPT to scGPT fine-tuned under identical conditions, or drop the cross-paper comparison entirely and restrict claims to what can be demonstrated with controlled experiments.
- **Describe Ember-V1** (architecture, training data, parameter count, domain-specific pre-training) to contextualize the interpretability findings.
- **Add confidence intervals or standard deviations** to all main results, particularly the generative LLM experiments (Tables 2, 7).
- Consider restructuring the paper to treat scMPT as an illustrative application of the analytical findings rather than the headline contribution, or substantially expand the experimental validation of scMPT to match the breadth of the claims.

## Score and Decision

MY FINAL SCORE: <score>4.5</score>
MY FINAL DECISION: <decision>Reject</decision>